Key facts
- The Blue Box’s last known valuation is $10.4M (Jul 2025).
- It has raised $5.5M; the latest was Early Stage VC ($3.5M) in Jul 2025.
- Notable investors include MassChallenge, Berkeley SkyDeck, 4YFN, CancerX (USA), Unconventional Ventures — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for The Blue Box
- ·The full record, as it builds
Funding rounds
No funding rounds for The Blue Box are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About The Blue Box
Developer of a breast cancer detection device designed to detect early signs of late-stage breast cancer at home. The company's device uses a urine sample and an artificial intelligence algorithm and contains chemical sensors that are specifically sensitive to some breast cancer biomarkers, enabling women to test for breast cancer at home.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 10
- Website
- thebluebox.ai/
- Ownership
- Privately Held (backing)
The Blue Box doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in The Blue Box shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on The Blue Box in its N-PORT filings yet. We sweep new filings monthly.